Increased Prevalence of Migraines Will Drive the Global Migraine Drugs Market through 2019: TechNavio

Renewable energy


London, 30 January 2015 – An increased prevalence of migraine headaches has resulted in the growth of the Global Migraine Drugs Market, which is expected to post a CAGR of 3.54 percent from 2014-2019, says research firm TechNavio.

About the Report

Migraines are characterized by repeated attacks of severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Every year, this disease affects millions of people around the globe irrespective of their age, race or gender.

“According to the WHO, 47 percent of adults worldwide are estimated to suffer from headache disorders, of which more than 10 percent are reportedly suffering from migraines,” says Faisal Ghaus, Vice President of TechNavio.

The report also highlights an increase in strategic alliances in the market. Commercial agreements are proving to be highly beneficial, since the distribution networks of both developing partners are being used to commercialize the drug.

“Different vendors in the market are forming extensive strategic alliances to increase their market share,” says Ghaus.

The market is extremely competitive and is dominated by seven vendors, namely, Abbott Laboratories, Allergen, Eisai, Endo International, GlaxoSmithKline, Impax Laboratories and Pfizer. As a result of intense competition, they are joining hands to manufacture and market their drugs.

Key Information Covered in the Report:

Market segmentation, size and forecast through 2019

Market Growth Drivers:

Market Challenges:

Market Trends:

  • Increase in Strategic Collaborations
  • For a full detailed list, view our report.

Key Vendors:

  • Abbott Laboratories Ltd.
  • Allergan Inc.
  • Eisai Co. Ltd.
  • Endo International plc

Other Prominent Vendors:

  • Almirall
  • Boehringer Ingelheim
  • Eli Lilly
  • IntelGenx Technologies….